<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        47-212-96
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1996
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FELDENE 20MG DISPERSABLE TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIROXICAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Dispersible tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        22.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group: NON-STEROIDAL ANTI-INFLAMMATORY - ATC code: M01AC01.<br />Before prescribing piroxicam, your doctor should assess the benefits this medicine may have for you&nbsp;considering the risk of developing side effects. When you use this medicine, your doctor may require&nbsp;you to undergo regular medical examinations, and will tell you how often you should be examined.</p><p>FELDENE 20 mg dispersible tablet is used to relieve the symptoms of osteoarthritis (degenerative joint&nbsp;disease), rheumatoid arthritis, and ankylosing spondylitis (disease of the joints of the spine). These&nbsp;symptoms include swelling, stiffness and joint pain. Feldene is not a cure for arthritis, and will only&nbsp;provide relief for as long as you continue to take it.<br />Your doctor will only prescribe piroxicam if relief from symptoms with other anti-inflammatories&nbsp;(NSAIDs) is not sufficient</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Never take FELDENE 20 mg dispersible tablet:<br />&bull; if you are allergic to the active substance or to any of the other ingredients of this medicine, listed&nbsp;in section 6,&nbsp;<br />&bull; if you are pregnant, from the start of the 6th month of pregnancy (beyond 24 weeks ofamenorrhoea),<br />&bull; history of allergy or asthma triggered by taking this medicine or another similar medicine,&nbsp;particularly other non-steroidal anti-inflammatories, aspirin,<br />&bull; history of severe skin reactions such as exfoliative dermatitis (severe reddening of the skin, with&nbsp;skin peeling off in scales or layers), vesiculobullous reactions (Stevens-Johnson syndrome &mdash; a&nbsp;condition in which the skin bleeds, with red blisters, erosion and crusting) or toxic epidermal&nbsp;necrolysis (also known as Lyell&#39;s syndrome, a severe skin condition characterized by the presence&nbsp;of blisters and detachment of the upper layer of the skin),<br />&bull; if you have, or have a history of, ulcers, bleeding or perforation of the stomach or of the intestine,<br />&bull; if you have gastrointestinal disorders or a history of gastrointestinal disorders (inflammation of the&nbsp;stomach or intestines) that predispose you to bleeding disorders such as ulcerative colitis, Crohn&#39;&nbsp;disease, gastrointestinal cancers or diverticulitis (an inflammation or infection of the pouches of the&nbsp;colon wall),<br />&bull; if you have severe heart disease,<br />&bull; if you have severe liver disease,<br />&bull; if you have severe kidney disease,<br />&bull; children under 15 years of age.<br />&bull; if you have had aortocoronary bypass surgery (heart surgery to bypass a narrowed artery),<br />&bull; if you are taking mifamurtide.<br />If any of these circumstances apply to you, you must not take piroxicam.</p><p>Talk to your doctor&nbsp;immediately<br />IF IN DOUBT, BE SURE TO ASK YOUR DOCTOR OR PHARMACIST FOR ADVICE.<br /><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking FELDENE 20 mg, dispersible tablet.<br /><strong>Warnings</strong><br />THIS MEDICINE SHOULD ONLY BE USED UNDER MEDICAL SUPERVISION.<br />Take care when taking FELDENE 20 mg dispersible tablet, and always inform your doctor before taking&nbsp;it. As with all other non-steroidal anti-inflammatory agents (NSAIDs), FELDENE 20 mg dispersibletablet, can cause serious gastrointestinal reactions, such as pain, bleeding, ulceration and perforation.&nbsp;Administration of doses greater than 20 mg per day increases the risk of gastrointestinal side effects.</p><p>Medicines such as FELDENE 20 mg dispersible tablet, may increase the risk of heart attack&nbsp;(&quot;myocardial infarction&quot;) or stroke. The risk is greater with high doses and prolonged treatment&nbsp;durations.&nbsp;<br />Never exceed the recommended dose or duration of treatment.<br />If you have heart problems, if you have had a stroke or if you think you have risk factors for this type&nbsp;of condition (for example if you have high blood pressure, diabetes, high cholesterol or if you smoke),&nbsp;talk to your doctor or pharmacist.<br />TELL YOUR DOCTOR:<br />&bull; if you have a history of asthma associated with chronic rhinitis, chronic sinusitis or nasal polyps.&nbsp;Use of this product may cause asthma, especially among certain people allergic to acetylsalicylic&nbsp;acid (aspirin) or nonsteroidal anti-inflammatories (see &quot;Never take FELDENE 20 mg, dispersible&nbsp;tablet&quot;),<br />&bull; if you are taking anticoagulant treatment. This medicine may cause serious gastrointestinal effects.</p><p><br />STOP THE TREATMENT IMMEDIATELY AND INFORM YOUR DOCTOR:<br />&bull; if you experience stomach pain, or any signs of gastrointestinal bleeding (vomiting blood, blood in&nbsp;the stools or black stools),<br />&bull; if you experience an allergic reaction, in the form of a rash, a swelling of the face, wheezing or&nbsp;difficulty breathing,<br />&bull; in case of anomalies or worsening of your liver function.<br />&bull; if you develop a rash or skin symptoms, you should stop taking FELDENE 20 mg dispersible tablet&nbsp;immediately, seek prompt medical advice and tell your doctor that you are taking this medicine.<br /><strong>Precautions</strong>&nbsp;<br />This medicine is available in other dose forms that may be more appropriate.Because of the need to adjust the treatment, it is important to NOTIFY THE DOCTOR who writes the&nbsp;prescription:<br />&bull; if you have a history of digestive problems (hiatus hernia, stomach or duodenal ulcer,&nbsp;gastrointestinal bleeding),<br />&bull; if you have a heart, liver, or kidney disorder.</p><p>&nbsp;If you are over 70 years of age, your doctor may need to decrease the duration of treatment and see you&nbsp;more frequently while you are using piroxicam.<br />&bull;If you are over 70 years of age, or are taking medicines such as corticosteroids or certain medicines used&nbsp;to treat depression called selective serotonin reuptake inhibitors (SSRIs), or acetylsalicylic acid to&nbsp;prevent the formation of blood clots, or if you drink alcohol, your doctor may prescribe you another&nbsp;<br />medicine together with FELDENE 20 mg dispersible tablet, to protect your stomach lining.You should not take this medicine if you are over 80 years of age.<br />If you have or have had any medical problems or allergies, or if you are not sure how to take piroxicam,&nbsp;<br />talk to your doctor before using this medicine.<br />Make sure you have told your doctor about any other medicines you are taking, including those you&nbsp;have bought without a prescription.<br />IF YOU ARE NOT SURE, ASK YOUR DOCTOR OR PHARMACIST.<br /><strong>Children and adolescents</strong><br />Not applicable.<br /><strong>Other medicines and FELDENE 20 mg dispersible tablet</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Certain medicines can disrupt the action of other medicines. Your doctor may limit your use of&nbsp;<br />piroxicam or other medicines, and he or she may prescribe alternative medicines. It is particularly&nbsp;<br />important to tell your doctor:<br />&bull; if you are taking mifamurtide,<br />&bull; if you are taking aspirin or any other nonsteroidal anti-inflammatory for pain relief<br />&bull; if you are taking oral steroids. These are medicines given to treat a variety of ailments such as&nbsp;<br />allergies and hormonal imbalances<br />&bull; if you are taking anticoagulants, such as coumarin-type derivatives (warfarin), or direct oral&nbsp;<br />anticoagulants (for example apixaban, dabigatran, rivaroxaban), medicines used to prevent the&nbsp;<br />formation of blood clots<br />&bull; if you are taking certain medicines called selective serotonin reuptake inhibitors (SSRIs) for the&nbsp;<br />treatment of depression, lithium<br />&bull; if you are taking medicines such as aspirin, to prevent platelet aggregation<br />&bull; if you are taking methotrexate<br />&bull; if you are taking heparin<br />&bull; If you are taking other potassium-sparing medicines<br />&bull; if you are taking pemetrexed (used in the treatment of lung cancer)&nbsp;<br />&bull; if you are taking ciclosporin, tacrolimus (used to lower the body&#39;s defences in case of transplants or&nbsp;<br />certain skin diseases)<br />&bull; if you are taking medicines to treat high blood pressure,<br />&bull; if you are taking diuretics,<br />&bull; if you are taking deferasirox<br />&bull; if you are taking tenofovir disoproxil,<br />&bull; if you are taking platelet anti-aggregants,<br />&bull; if you are taking cobimetinib,<br />&bull; if you are taking mixed adrenergic-serotonergic drugs,<br />&bull; if you are taking nicorandil.<br /><strong>FELDENE 20 mg dispersible tablet with food and drink</strong><br />Not applicable.<br /><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby,&nbsp;ask your doctor or pharmacist for advice before taking any medicine</p><p><strong>Pregnancy</strong><br /><strong>Before the beginning of the 6th month of pregnancy</strong> (up to the 24th week of amenorrhoea), you should&nbsp;not take this medication except in case of absolute necessity determined by your doctor, due to the&nbsp;potential risk of miscarriages or deformities. In this case, the dose should be as low as possible and the&nbsp;duration of treatment as short as possible. The health care professionals should consider ultrasound&nbsp;monitoring of amniotic fluid if NSAID treatment extends beyond 48 hours and discontinue the NSAID&nbsp;if oligohydramnios is found<strong>.After 12 weeks without menstruation</strong>, this medicine can cause kidney problems in your baby, if&nbsp;taken for several days, which can lead to a low level of the amniotic fluid surrounding the baby&nbsp;(oligoamnios). Narrowing of the blood vessels (constriction of the arterial canal) in your baby&rsquo;s heart&nbsp;may occur after 20 weeks without menstruation. If several days of treatment are needed, your doctor&nbsp;may recommend additional monitoring.<br /><strong>From the start of the 6th month until the end of pregnancy</strong> (beyond 24th week of amenorrhoea), this&nbsp;medicine is <strong>contraindicated,</strong> which means that you<strong> MUST NOT </strong>take this medicine, because the effects&nbsp;on your baby, especially on his/her heart, lungs and/or kidneys, can be serious or even fatal, even with&nbsp;a single dose. This can also affect you and your baby by increasing bleeding and lead to a delayed or&nbsp;longer delivery than expected.If you have taken this medicine while pregnant, talk to your obstetrician-gynaecologist immediately, to&nbsp;make sure that you are offered suitable monitoring if necessary.</p><p><br /><strong>Breast-feeding</strong><br />As this medicine passes into breast milk, it is not recommended to use it while breast-feeding.</p><p><br /><strong>Fertility</strong><br />Like all non-steroidal anti-inflammatories (NSAIDs), this medicinal product can alter fertility in&nbsp;women and cause difficulties in becoming pregnant, being reversible when the treatment is&nbsp;discontinued. Tell your doctor if you are planning to become pregnant or having difficulties&nbsp;conceiving.</p><p><br /><strong>Driving vehicles and using machines</strong><br />In rare cases, taking this medicine may cause dizziness and drowsiness.&nbsp;</p><p><br /><strong>FELDENE 20 mg dispersible tablet contains lactose and sodium.</strong><br />This medicine contains lactose. If your doctor has informed you of an intolerance to certain sugars,&nbsp;<br />contact your doctor before taking this medicine.<br />This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &quot;sodiumfree&quot;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or&nbsp;pharmacist if you are not sure.<br />Your doctor will carry out regular medical examinations to ensure you are taking the best dose of&nbsp;piroxicam for you. He or she will adapt your treatment to ensure that you receive the lowest possible&nbsp;dose that ensures relief of your symptoms. Do not, under any circumstances, change the dose yourself&nbsp;without first talking to your doctor.<br /><u><strong>Posology</strong></u><br />Always take this medicine exactly as your doctor has told you. If in doubt, consult your doctor or&nbsp;pharmacist.<br /><strong>Adults and elderly patients</strong><br />The maximum daily dose is 20 mg of piroxicam, taken only once per day.</p><p><strong>If you are over 70 years old, your doctor may prescribe you a lower daily dose and / or reduce the&nbsp;duration of treatment.</strong></p><p>In combination with piroxicam, your doctor is likely to prescribe another medicine to protect your&nbsp;stomach and intestine against undesirable side effects</p><p>YOU MUST CONFORM STRICTLY TO YOUR DOCTOR&#39;S PRESCRIPTION IN ALL CASES.<br /><strong>Do not increase your dose</strong><br />If you feel that the medicine is not effective, talk to your doctor as soon as possible.<br /><u><strong>Method of administration</strong></u><br />Oral use.<br />The tablet is to be swallowed as is or dissolved in a large glass of water.<br /><strong><u>Frequency of administration</u></strong><br />The tablet should be taken at meal times.<br />YOU MUST CONFORM STRICTLY TO YOUR DOCTOR&#39;S PRESCRIPTION IN ALL CASES.<br /><u><strong>Duration of treatment</strong></u><br />YOU MUST CONFORM STRICTLY TO YOUR DOCTOR&#39;S PRESCRIPTION IN ALL CASES.<br /><strong>If you have taken more FELDENE 20 mg dispersible tablet than you should have:</strong><br />Consult your doctor or pharmacist immediately.<br /><strong>If you forget to take FELDENE 20 mg dispersible tablet:</strong><br />Take it as soon as you remember. If the time of your next dose is near, do not take the dose that you&nbsp;<br />missed, take only the next dose at the normal time. Do not take a double dose to make up for the missed&nbsp;<br />dose.<br /><strong>If you stop taking FELDENE 20 mg dispersible tablet:</strong><br />Not applicable.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Medicines such as FELDENE 20 mg dispersible tablet, may increase the risk of heart attack&nbsp;(&quot;myocardial infarction&quot;) or stroke.<br />The following may occur:<br /><strong>Common adverse effects (may affect up to 1 in 10 people):</strong><br /><u><em>Effects on the metabolism and nutrition:</em></u><br />&bull; loss of appetite (anorexia).<br /><u>Effects on the nervous system:&nbsp;</u><br />&bull; headache, dizziness, drowsiness, vertigo.<br /><u>Effects on the ear:</u><br />&bull; buzzing in the ears.<br /><u>Digestive effects:</u><br />&bull; heavy feeling in the abdomen, nausea, constipation, abdominal discomfort, flatulence, abdominal&nbsp;pain, diarrhoea, vomiting, indigestion.<br /><u>Effects on the skin:&nbsp;</u><br />&bull; skin rash, itching (pruritus).<br /><u>General effects:</u><br />&bull; swelling of certain parts of the body due to liquid infiltrating into the tissues (oedema, particularly&nbsp;of the legs).<br /><u>Effects on the biological test:</u><br />&bull; reversible elevations of blood urea nitrogen, transitory or reversible increased serum transaminase&nbsp;levels (enzymes found inside cells),<br />&bull; decrease in hemoglobin (a protein in red blood cells that carries oxygen to the tissues and gives&nbsp;blood its red color) and hematocrit (percentage of the volume occupied by red blood cells compared&nbsp;to the total blood volume) unassociated with obvious gastro-intestinal bleeding.<br />If any of the side effects listed above occur, you must notify a doctor immediately and consider stopping&nbsp;treatment.<br /><strong>Uncommon adverse effects (may affect up to 1 in 100 people):</strong><br /><u>Effects on the eye:&nbsp;</u></p><p>&bull; blurred vision.<br /><u>Cardiac effects:</u><br />&bull; perception of heartbeats (palpitations).<br /><u>Digestive effects:&nbsp;</u><br />&bull; inflammation in the mouth (stomatitis).<br /><u>Effects on the biological test:</u><br />&bull; reversible elevations of creatinine in the blood (may be a sign of a kidney problem).<br />If any of the side effects listed above occur, you must notify a doctor immediately and consider stopping&nbsp;<br />treatment.</p><p><br /><strong>Adverse effects with not known frequency (frequency cannot be estimated from the available&nbsp;data):</strong><br /><u>Effects on the blood:</u><br />&bull; abnormally low levels of certain cells in the blood which may result in paleness or intense fatigue&nbsp;(red blood cells), signs of infection or unexplained fever (white blood cells), bleeding from the nose&nbsp;or gums (platelets) or abnormally high levels of other cells in the blood (eosinophils).<br /><u>Effects on the immune system:&nbsp;</u><br />&bull; severe allergic reactions (anaphylactic reactions),<br />&bull; severe allergic reactions related to the appearance of antibodies (serum sickness).<br /><u>Effects on the metabolism and nutrition:</u><br />&bull; abnormally high blood glucose levels (hyperglycaemia),&nbsp;<br />&bull; abnormal decrease in blood glucose levels (hypoglycaemia),&nbsp;<br />&bull; fluid retention, sodium retention,&nbsp;<br />&bull; high level of potassium in the blood (hyperkalemia).<br /><u>Effects on the nervous system:&nbsp;</u><br />&bull; neck stiffness with fever and sometimes coma (aseptic meningitis),&nbsp;<br />&bull; sensitivity disorder that includes stinging, numbness and tingling in a limb, usually in the extremities&nbsp;(paresthesia).<br /><u>Effects on the eye:&nbsp;</u><br />&bull; eye irritation, swollen eyes.<br /><u>Effects on the ear:</u><br />&bull; decreased hearing.<br /><u>Vascular effects:&nbsp;</u><br />&bull; acute inflammation of the walls of blood vessels (vasculitis),&nbsp;<br />&bull; high blood pressure (hypertension).<br /><u>Respiratory effects:</u><br />&bull; contraction of the lungs that causes temporary obstruction of the airways (bronchospasm),&nbsp;<br />&bull; difficulty in breathing (dyspnea),&nbsp;<br />&bull; nosebleed (epistaxis),&nbsp;<br />&bull; asthma attack.<br /><u>Digestive effects:&nbsp;</u><br />&bull; gastrointestinal perforations and ulcers,&nbsp;<br />&bull; inflammation of the pancreas (pancreatitis),&nbsp;<br />&bull; digestive bleeding (blood coming up to the mouth (haematemesis) or in the stool, black colored&nbsp;stool (melena). This type of bleeding becomes more frequent with higher doses,<br />&bull; inflammation of the stomach lining (gastritis).<br /><u>Hepatobiliary effects:</u><br />&bull; severe liver inflammation that can be fatal,<br />&bull; jaundice (yellowing of the skin or eyes).<br /><u>Effects on the skin:&nbsp;</u><br />&bull; blistering, often associated with itching and burning sensation (hives) on the face with difficulty&nbsp;breathing (angioedema),<br />&bull; serious skin reactions such as rash, blistering or peeling of the skin (Stevens-Johnson syndrome,&nbsp;toxic epidermal necrolysis (Lyell&#39;s syndrome), DRESS syndrome, bullous skin reactions, exfoliative&nbsp;dermatitis, erythema multiforme),<br />&bull; strong skin reaction when skin is exposed to the sun or UV rays</p><p>&bull; &nbsp;fixed drug eruption (may look like round or oval patches of redness and swelling of the skin),&nbsp;</p><p>&bull; blistering, often associated with itching and burning sensation (hives),<br />&bull; vascular purpura resulting in haemorrhagic spots on the skin (Henoch-Schonlein),&nbsp;<br />&bull; progressive detachment of the nail (onycholysis),&nbsp;<br />&bull; worsening of blistering, often associated with itching and burning sensation (chronic hives),&nbsp;<br />&bull; hair loss (alopecia).<br /><u>Effects on the kidney:&nbsp;</u><br />&bull; abnormal kidney filtration function (functional acute renal failure, nephrotic syndrome),&nbsp;<br />&bull; inflammation of certain kidney tissues (glomerulonephritis, interstitial nephritis),&nbsp;<br />&bull; necrosis of part of the kidney (papillary necrosis, acute tubular necrosis).<br /><u>Reproductive effects:</u><br />&bull; decreased fertility in women.&nbsp;<br /><u>General and administration site effects:</u><br />&bull; malaise.<br /><u>Effects on the biological test:</u><br />&bull; positive antinuclear antibody test,<br />&bull; transitory or reversible elevation of bilirubin in the blood,&nbsp;<br />&bull; platelet aggregation decreased and bleeding time increased.<br />If any of the side effects listed above occur, you must notify a doctor immediately and consider stopping&nbsp;treatment.<br /><strong>Reporting of side effects&nbsp;</strong><br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not&nbsp;listed in this leaflet. By reporting side effects, you can help provide more information on the safety of&nbsp;this medicine&nbsp;</p><p><strong>To Report side effects</strong><br />&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>&bull; Saudi Arabia</strong></p><p>National Pharmacovigilance Center (NPC)<br />Call center: 19999&nbsp;<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/&nbsp;</p></td></tr></tbody></table><p><br />&bull; <strong>Other GCC States</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>Please contact the relevant competent authority</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Store below 25&deg;C.&nbsp;</li><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date, which is indicated on the box and vial after &ldquo;EXP. &rdquo;</li><li>The expiry date refers to the last day of that month.&nbsp;</li><li>This medicine should be stored below 25&deg;C away from heat and moisture.&nbsp;</li><li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to&nbsp;throw away medicines you no longer use. These measures will help protect the environment</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is:<br />Piroxicam .................................................................................................................................. 20.00 mg For one tablet.<br />&bull; The other ingredients are:&nbsp;<br />Lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, sodium stearyl fumarate (see&nbsp;<br />section 2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This medicine comes in the form of a dispersible tablet. Box of 10
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing authorisation holder</strong><br />SPIMACO, Al-Qassim Pharmacaeutical Plant, Saudi Arabia</p><p><br /><strong>Manufacturer&nbsp;</strong><br />SPIMACO, Al-Qassim Pharmacaeutical Plant, Saudi Arabia<br />Under license from: Pfizer Inc, New York, U.S.A.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">الفئة الدوائية العالجية: مضادات االلتهاب غير الستيرويدية - رمز نظام التصنيف الكيميائي العالجي التشريحي<br />. M01AC01:(ATC)<br />قبل أن يصف لك طبيبك العالج ببيروكسيكام، ينبغي أن يقيم الفوائد التي قد تعود عليك من هذا الدواء مقارنة بمخاطر اإلصابة&nbsp;<br />باآلثار الجانبية. عند استخدامك لهذا الدواء، قد يطلب منك طبيبك الخضوع لفحوصات طبية بشكل منتظم، وسيخبرك كم مرة&nbsp;<br />ينبغي عليك أن تخضع للفحص.<br />تستخدم أقراص فلدين ٢٠ ملجم سريعة الذوبان في تخفيف أعراض الفصال العظمي )مرض المفاصل التنكسي(، والتهاب المفاصل&nbsp;الروماتويدي، والتهاب الفقار المقسط )مرض يصيب مفاصل العمود الفقري(. تتضمن هذه األعراض التورم، والتيبس، وألم المفاصل.&nbsp;<br />لا يشفي فلدين مرض التهاب المفاصل، وسيعمل فقط على تخفيف أعراض المرض طوال فترة تناولك له.<br />سيصف لك طبيبك بيروكسيكام فقط إذا كان تخفيف األعراض باستخدام مضادات االلتهاب غير الستيرويدية)NSAIDs ً )ليس كافيا</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال أقراص فلدین ۲۰ ملجم سریعة الذوبان :</strong><br />&bull; إذا كان لدیك حساسیة تجاه المادة الفعالة أو تجاه أي من المكونات الأخرى لھذا الدواء المدرجة في القسم ٦،<br />&bull; ِ إذا كنت ً حاملا، منذ بدایة الشھر السادس من الحمل (بعد ۲٤ ً أسبوعا من انقطاع الحیض خلال عمر الإنجاب )،<br />&bull; إذا كان لدیك تاریخ من الإصابة بالحساسیة أو الربو الناجم عن تناول ھذا الدواء أو دواء آخر مشابھ، خاصة مضادات الالتھاب غیر&nbsp;الستیرویدیة الأخرى، الأسبرین،<br />&bull; إذا كان لدیك تاریخ من الإصابة ب التفاعلات الجلدیة الشدیدة مثل التھاب الجلد التقشري (احمرار شدید للجلد، مع تقشر الجلد في&nbsp;صورة قشور أو طبقات)، أو تفاعلات حویصلیة فقاعیة (متلازمة ستیفنز جونسون &mdash; حالة یصاب فیھا الجلد بالنزیف المصحوب&nbsp;<br />ً ببثور حمراء، وتآكل وتقشر)، أو تقشر الأنسجة المتموتة البشرویة التسممي (المعروف أیضا بمتلازمة لیل، وھي حالة جلدیة شدیدة&nbsp;<br />تتصف بوجود بثور وانفصال الطبقة السطحیة من الجلد)،<br />&bull; ً إذا كنت مصابا أو لدیك تاریخ من الإصابة بالقرح أو النزیف أو الانثقاب في المعدة أو الأمعاء،&nbsp;<br />&bull; ً إذا كنت مصابا باضطرابات معدیة معویة أو لدیك تاریخ من الإصابة بالاضطرابات المعدیة المعویة (التھاب المعدة أو الأمعاء)&nbsp;<br />التي تجعلك عرضة للإصابة بالاضطرابات النزفیة مثل التھاب القولون التقرحي، أو مرض كرون، أو السرطانات المعدیة المعویة،&nbsp;<br />أو التھاب الرتج (إصابة أكیاس جدار القولون بالالتھاب أو العدوى)،<br />&bull; ً إذا كنت مصابا بمرض شدید بالقلب،<br />&bull; ً إذا كنت مصابا بمرض شدید في الكبد،<br />&bull; ً إذا كنت مصابا بمرض شدید بالكلى،<br />&bull; الأطفال الأصغر من ۱٥ً عاما.<br />&bull; إذا كنت قد خضعت لجراحة تركیب مجازة أبھریة تاجیة (جراحة قلب لتجاوز شریان متضیق)</p><p dir="RTL">&bull; إذا كنت تتناول میفامورتید.&nbsp;<br />إذا كانت أي من ھذه الظروف تنطبق علیك، یجب ألا تتناول بیروكسیكام. تحدث إلى طبیبك على الفور<br />إذا كنت غیر واثق مما ینبغي علیك فعلھ، فاحرص على استشارة طبیبك أو الصیدلي.&nbsp;<br />الاحتیاطات عند استعمال أقراص فلدین ۲۰ ملجم سریعة الذوبان&nbsp;<br />تحدث إلى طبیبك أو الصیدلي قبل تناول أقراص فلدین ۲۰ ملجم سریعة الذوبان.&nbsp;<br /><strong>تحذیرات&nbsp;</strong><br />ینبغي استخدام ھذا الدواء فقط تحت إشراف طبي.&nbsp;<br />توخ الحذر عند تناول أقراص فلدین ۲۰ ملجم سریعة الذوبان، ً وأبلغ طبیبك دائما قبل تناولھا. كما ھو الحال مع جمیع العوامل المضادة&nbsp;<br />للالتھاب غیر الستیرویدیة الأخرى ( NSAIDs ،(قد تسبب أقراص فلدین ۲۰ ملجم سریعة الذوبان تفاعلات معدیة معویة خطیرة كالألم،&nbsp;<br />والنزیف، والتقرح، والانثقاب. إن استعمال جرعات أكبر من ۲۰ ً ملجم یومیا یزید من خطر الإصابة بآثار جانبیة معدیة معویة.&nbsp;<br />قد تزید الأدویة مثل أقراص فلدین ۲۰ ملجم سریعة الذوبان من خطر الإصابة بالأزمة القلبیة (&quot;احتشاء عضلة القلب&quot;) أو السكتة&nbsp;<br />الدماغیة. ویزید الخطر مع الجرعات العالیة ومدد العلاج المطولة.&nbsp;<br />لا تتخط أبدًا الجرعة أو مدة العلاج الموصى بھا.<br />إذا كنت مصابا بمشكلات قلبیة، أو إذا كنت قد أصبت من قبل بسكتة دماغیة، أو إذا كنت تعتقد أن لدیك عوامل خطر للإصابة بھذا النوع&nbsp;من الحالات (على سبیل المثال، إذا كنت مصابا بضغط الدم المرتفع، أو السكري، أو ارتفاع مستوى الكولیسترول، أو إذا كنت تدخن)،&nbsp;فتحدث إلى طبیبك أو الصیدلي.&nbsp;<br />أخبر طبیبك:<br />&bull; إذا كان لدیك تاریخ من الإصابة بالربو المرتبط بالالت ھاب المزمن لغشاء الأنف المخاطي، أو بالتھاب الجیوب الأنفیة المزمن، أو&nbsp;<br />بالسلائل الأنفیة. یمكن أن یسبب استخدام ھذا المنتج الإصابة بالربو، خاصة في بعض الأشخاص المصابین بحساسیة تجاه حمض&nbsp;<br />الأسیتیل سالیسیلیك (الأسبرین) أو تجاه مضادات الالتھاب غیر الستیرویدیة (انظر القسم &quot;قبل القیام بتناول أو استعمال أقراص&nbsp;<br />فلدین ۲۰ ملجم سریعة الذوبان&quot;)،&nbsp;<br />&bull; ً إذا كنت تتناول علاج ً ا مضادًا للتخثر. یمكن أن یسبب ھذا الدواء آثارا معدیة معویة خطیرة.&nbsp;</p><p dir="RTL"><br />أوقف العلاج على الفور وأبلغ طبیبك:<br />&bull; إذا أصبت بألم في المعدة، أو بأي علامات للنزیف المعدي المعوي، (تقیؤ الدم، أو وجود دم في البراز، أو براز أسود)،&nbsp;<br />&bull; إذا أصبت بتفاعل حساسیة، في صورة طفح جلدي، أو تورم للوجھ، أو أزیز، أو صعوبة في التنفس.&nbsp;<br />&bull; في حالة وجود اضطرابات في وظائف الكبد لدیك أو تفاقم حالتھا.&nbsp;<br />&bull; إذا عانیت من طفح جلدي أو أعراض جلدی ً ة، ینبغي أن تتوقف فورا عن تناول أقراص فلدین ۲۰ ملجم سریعة الذوبان، واطلب المشورة&nbsp;<br />الطبیة على وجھ السرعة وأخبر طبیبك أنك تتناول ھذا الدواء.&nbsp;<br /><strong>احتیاطات&nbsp;</strong><br />یتوفر ھذا الدواء في أشكال جرعات أخرى قد تكون أكثر ملاءمة.&nbsp;<br />بسبب الحاجة لتعدیل العلاج، من المھم إخبار الطبی ب الذي یكتب لك الوصفة الطبیة:&nbsp;<br />&bull; إذا كان لدیك تاریخ من الإصابة بمشكلات ھضمیة (فتق حجابي، أو قرحة في المعدة أو في الاثني عشر، أو نزیف معدي معوي)،&nbsp;<br />&bull; ً إذا كنت مصابا باضطراب في القلب أو الكبد أو الكلى.&nbsp;<br />إذا كنت تبلغ من العمر أكثر من ۷۰ً عام ً ا، فقد یحتاج طبیبك إلى تقلیل مدة العلاج ورؤیتك بصورة أكثر تكررا خلال فترة استخدامك&nbsp;<br />لبیروكسیكام.<br />إذا كنت تبلغ من العمر أكثر من ۷۰ً عاما، أو كنت تتناول أدویة مثل الستیرویدات القشریة أو بعض الأدویة المستخدمة لعلاج الاكتئاب&nbsp;<br />تسمى مثبطات استرداد السیروتونین الانتقائیة (SSRI ،(أو حمض الأسیتیل سالیسیلیك لمنع تكون الجلطات الدمویة، أو إذا كنت تشرب&nbsp;<br />ً الكحولیات، فقد یصف لك الطبیب دواء آخر مع أقراص فلدین ۲۰ ملجم سریعة الذوبان لحمایة بطانة معدتك.<br />ینبغي ألا تتناول ھذا الدواء إذا كنت تبلغ من العمر أكثر من ۸۰ً عاما.&nbsp;<br />إذا كنت تعاني أو سبق لك أن عانیت من مشكلات طبیة أو حالات حساسیة، أو إذا لم تكن متأكدًا من كیفیة تناول بیروكسیكام، فتحدث&nbsp;<br />إلى طبیبك قبل استخدام ھذا الدواء.&nbsp;<br />احرص على إبلاغ طبیبك بأي أدویة أخرى تتناولھا، بما في ذلك الأدویة التي قمت بشرائھا دون وصفة طبیة.</p><p dir="RTL">إذا كنت غیر متأكد مما علیك فعلھ، فاسأل طبیبك أو الصیدلي.</p><p dir="RTL">الأطفال والمراھقون&nbsp;<br />لا ینطبق.&nbsp;<br />التداخلات الدوائیة من أخذ ھذا المستحضر مع أي أدویة أخرى أو أعشاب أو مكملات غذائیة&nbsp;<br />ً أخبر طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرا أو قد تتناول أي أدویة أخرى.&nbsp;<br />بعض الأدویة یمكن أن تعطل عمل الأدویة الأخرى. قد یقید طبیبك استخدامك لبیروكسیكام أو الأدویة الأخرى، وقد یصف لك أدویة&nbsp;<br />بدیلة. من المھم بشكل خاص أن تخبر طبیبك:<br />&bull; إذا كنت تتناول میفامورتید،&nbsp;<br />&bull; ً إذا كنت تتناول الأسبرین أو أیا من مضادات الالتھاب غیر الستی رویدیة الأخرى لتخفیف الألم&nbsp;<br />&bull; إذا كنت تتناول الستیرویدات التي تؤخذ عبر الفم. تعطى ھذه الأدویة لعلاج مجموعة مختلفة من الأمراض مثل حالات الحساسیة&nbsp;<br />واختلال التوازن الھرموني<br />&bull; إذا كنت تتناول مضادات التخثر، مثل المشتقات من نوع كومارین (وارفارین)، أو مضادات التخثر التي تؤخذ عبر الفم مباشرة<br />(على سبیل المثال، أبیكسابان، دابیجاتران، ریفاروكسابان)، وھي أدویة تستخدم لمنع تكون الجلطات الدمویة&nbsp;<br />&bull; إذا كنت تتناول أدویة معینة تسمى مثبطات استرداد السیروتونین الانتقائیة (SSRIs (لعلاج الاكتئاب، لیثیوم<br />&bull; إذا كنت تتناول أدویة مثل الأسبرین، لمنع تكدس الصفیحات الدمویة&nbsp;<br />&bull; إذا كنت تتناول میثوتریكسات&nbsp;<br />&bull; إذا كنت تتناول ھیبارین&nbsp;<br />&bull; إذا كنت تتناول أدویة أخرى حافظة للبوتاسیوم<br />&bull; إذا كنت تتناول بیمیتریكسید (یستخدم في علاج سرطان الرئة)&nbsp;<br />&bull; إذا كنت تتناول سیكلوسبورین، تاكرولیموس (یستخدمان في خفض دفاعات الجسم في حالة عملیات الزرع أو في بعض الأمراض&nbsp;<br />الجلدیة)<br />&bull; إذا كنت تتناول أدویة لعلاج ضغط الدم المرتفع،&nbsp;<br />&bull; إذا كنت تتناول مدرات البول،<br />&bull; إذا كنت تتناول دیفیراسیروكس&nbsp;<br />&bull; إذا كنت تتناول تینوفوفیر دیسوبروكسیل،<br />&bull; إذا كنت تتناول مضادات تكدس الصفائح الدمویة،<br />&bull; إذا كنت تتناول كوبیمیتینیب،&nbsp;<br />&bull; إذا كنت تتناول العقاقیر الأدرینالینیة السیروتونینیة المختلطة،&nbsp;<br />&bull; إذا كنت تتناول نیكوراندیل.<br /><strong>تناول أقراص فلدین ۲۰ ملجم سریعة الذوبان مع الطعام والشراب&nbsp;<br />لا ینطبق.&nbsp;</strong><br /><strong>الحمل والرضاعة&nbsp;</strong><br />ِ إذا كنت ً حاملا أو ترضعین رضاعة طبیعیة، أو تعتقدین أنك ربما تكونین حا ًملا ِ أو تخططین للحمل، فاستشیري طبیبك أو الصیدلي قبل&nbsp;<br />تناول أي دواء.&nbsp;<br /><strong>الحمل&nbsp;</strong><br /><strong>ِ قبل بدایة الشھر السادس من حملك </strong>(حتى مرور ۲٤ ً أسبوعا على انقطاع الحیض خلال عمر الإنجاب)، ینبغي تناول ھذا الدواء إلا في&nbsp;<br />ِ حالة الضرورة القصوى التي یحددھا طبیبك ً ، نظرا للخطورة المحتملة لحدوث حالات إجھاض أو تشوھات. في ھذه الحالة، ینبغي أن&nbsp;<br />تكون الجرعة منخفضة بأقصى قدر ممكن وأن تكون فترة العلاج قصیرة بقدر الإمكان. ینبغي لمتخصصي الرعایة الصحیة أن یضعوا&nbsp;<br />في الاعتبار مراقبة السائل الأمینوسي بالموجات فوق الصوتیة إذا امتد العلاج بمضادات الالتھاب غیر الستیرویدیة لأكثر من ٤۸ ساعة،&nbsp;<br />ُشف نقص في السائل الأمینوسي.&nbsp;<br />وإیقاف العلاج بمضادات الالتھاب غیر الستیرویدیة إذا اكت<br /><strong>بعد ۱۲ ً أسبوعا من انقطاع الحیض،</strong> یمكن لھذا الدواء أن یسبب مشكلات في الكلى لدى ِ طفلك إذا ِ تناولتھ لعدة أیام، إذ یمكن أن یؤدي&nbsp;<br />إلى نقص السائل الأمی نوسي المحیط بالجنین (قلة السائل السلوي). قد یحدث تضیق في الأوعیة الدمویة (ضیق القناة الشریانیة) في قلب&nbsp;<br />ِ طفلك بعد ۲۰ ً أسبوعا من انقطاع الحیض. إذا كان ت ھناك حاجة إلى تناول العلاج لعدة أیام ِ ، فقد یوصي طبیبك ب ِ إخضاعك لإشراف&nbsp;<br />إضافي.&nbsp;<br /><strong>منذ بدایة الشھر السادس حتى انتھاء الحمل</strong> (بعد ۲٤ ً أسبوعا من انقطاع الحیض خلال عمر الإنجاب)،&nbsp;ُيمنع استعمال ھذا الدواء مما&nbsp;<br />ِ یعني أنھ یجب عدم تناول ھذا الدواء لأن آثاره على طفلك، خاصة على قلبھ و/أو رئتیھ و/أو كلیتیھ، یمكن أن تكون خطیرة بل وممیتة&nbsp;<br />حتى مع تناول جرعة فردیة. یمكن لھذا ً أیضا أن یؤثر فی ِك و في ِ طفلك عن طریق زیادة النزیف وقد یؤدي إلى تأخر الولادة أو قد تستغرق&nbsp;<br />وًقتا أطول من المتوقع&nbsp;</p><p dir="RTL"><strong>إ</strong>ذا تناولت ِ ھذا الدواء أثناء حملك، فتحدثي مع أخصائي الولادة - ِ طبیب النساء الخاص بك على الفور للتأكد من توفر خطة مراقبة مناسبة&nbsp;<br />لك إذا لزم الأمر&nbsp;<br /><strong>الرضاعة الطبیعیة&nbsp;</strong><br />نتیجة لمرور ھذا الدواء إلى لبن الثدي، یوصى بعدم استخدام ھذا الدواء أثناء الرضاعة الطبیعیة.&nbsp;<br /><strong>الخصوبة&nbsp;</strong><br />مثل جمیع مضادات الالتھاب غیر الستیرویدیة (NSAIDs ،(یمكن لھذا المنتج الطبي أن یغیر الخصوبة عند النساء ویسبب صعوبات&nbsp;<br />في الحمل یمكن عكسھا عند التوقف عن تناول ِ العلاج. أخبري طبیبك إذا كنت تخططین للحمل أو تواجھین صعوبة في أن تصبحین&nbsp;<br />ً حاملا.<br /><strong>تأثیر أقراص فلدین ۲۰ ملجم سریعة الذوبان على القیادة واستخدام الآلات&nbsp;</strong><br />في حالات نادرة، یمكن أن یتسبب تناول ھذا الدواء في الدوار والنعاس.&nbsp;<br /><strong>معلومات ھامة حول بعض مكونات أقراص فلدین ۲۰ ملجم سریعة الذوبان&nbsp;<br />تحتوي أقراص فلدین ۲۰ ملجم سریعة الذوبان على اللاكتوز والصودیوم.&nbsp;</strong><br />یحتوي ھذا الدواء على اللاكتوز.اذا أخبرك طبیبك أنك لا تستطیع ت حمل بعض السكریات، فتواصل مع طبیبك قبل تناول ھذا الدواء.&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دومًا على تناول ھذا الدواء تمامًا كما أخبرك طبیبك أو الصیدلي. راجع طبیبك أو الصیدلي إذا لم تكن متأكدًا مما یجب علیك<br />فعلھ .<br />سیقوم طبیبك بإجراء فحوصات طبیة بشكل منتظم لیتأكد من أنك تتناول أفضل جرعة مناسبة لك من بیروكسیكام. وسیقوم بتكییف علاجك<br />لیتأكد من تلقیك لأقل جرعة ممكنة تضمن تخفیف الأعراض التي تعاني منھا. لا تقم تحت أي ظرف من الظروف بتغییر الجرعة من<br />تلقاء نفسك دون التحدث مع طبیبك أولًا .<br /><u><strong>الجرعا ت</strong></u><br />احرص دائمًا على تناول ھذا الدواء تمامًا كما أخبرك طبیبك. إذا كنت غیر واثق مما ینبغي علیك فعلھ، فاستشر طبیبك أو الصیدلي .<br /><strong>المرضى البالغون والمسنو ن</strong><br />الحد الأقصى للجرعة الیومیة ھو ۲۰ ملجم من بیروكسیكام، یتم تناولھا مرة واحدة یومیًا فقط .<br /><strong>إذا كنت تبلغ أكثر من ۷۰ عامًا من العمر، فقد یصف لك طبیبك جرعة یومیة أقل و/أو قد یقلل مدة العلاج .</strong><br />من المحتمل أن یصف لك طبیبك دواءً آخر لتناولھ بالتزامن مع بیروكسیكام لحمایة معدتك وأمعائك من الآثار غیر المرغوب فیھا .<br />في جمیع الحالات یجب علیك الالتزام بدقة بوصفة طبیبك.<br /><strong>لا تقم بزیادة جرعتك</strong></p><p dir="RTL">&nbsp;إذا شعرت بأن الدواء غیر فعال، فتحدث مع طبیبك في أقرب وقت ممكن.<br /><u><strong>طریقة الاستعما ل</strong></u><br />للاستخدام عبر الفم.<br />یتم بلع القرص كما ھو أو إذابتھ في كوب كبیر من الماء.<br /><u><strong>معدل الاستعما ل</strong></u><br />ینبغي تناول القرص في أوقات الوجبات.<br />في جمیع الحالات یجب علیك الالتزام بدقة بوصفة طبیبك.<br /><u><strong>مدة العلا ج</strong></u><br />في جمیع الحالات یجب علیك الالتزام بدقة بوصفة طبیبك.<br /><strong>الجرعة الزائدة من أقراص فلدین ۲۰ ملجم سریعة الذوبا ن</strong><br />استشر طبیبك أو الصیدلي على الفور.<br /><strong>نسیان تناول جرعة أقراص فلدین ۲۰ ملجم سریعة الذوبا ن</strong><br />تناول القرص بمجرد أن تتذكر. إذا اقترب موعد جرعتك التالیة، فلا تتناول الجرعة التي فاتتك، تناول فقط الجرعة التالیة في وقتھا<br />المعتاد. لا تتناول جرعة مضاعفة لتعویض جرعة فائتة .<br /><strong>التوقف عن تناول أقراص فلدین ۲۰ ملجم سریعة الذوبا ن</strong></p><p dir="RTL">لا ینطبق .<br />إذا كانت لدیك أي أسئلة إضافیة بشأن استخدام ھذا الدواء، فاسأل طبیبك أو الصیدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما ھو الحال مع جمیع الأدویة، یمكن أن یسبب ھذا الدواء آثارًا جانبیة، إلا أنھا لا تصیب الجمیع.<br />قد تزید الأدویة مثل أقراص فلدین ۲۰ ملجم سریعة الذوبان من خطر الإصابة بالأزمة القلبیة (&quot;احتشاء عضلة القلب&quot;) أو السكتة<br />الدماغیة.<br />قد یحدث ما یلي :<br /><strong>الآثار الضارة الشائعة (قد تصیب ما یصل إلى شخص واحد من بین كل ۱۰ أشخاص ) :</strong><br /><em><u>الآثار على الأیض والتغذیة :</u></em><br />&bull; فقدان الشھیة (القھم).<br /><u><em>الآثار على الجھاز العصبي:</em></u><br />&bull; الصداع، الدوار، النعاس، ال دوخة.<br /><u><em>الآثار على الأذن :</em></u><br />&bull; طنین في الأذنین.<br /><u><em>الآثار على الجھاز الھضمي :</em></u><br />&bull; الشعور ب ثقل في البطن، الغثیان، الإمساك، الشعور بانزعاج في البطن، امتلاء البطن بالغازات، ألم البطن، الإسھال، القيء، عسر<br />الھضم.<br /><u><em>الآثار على الجلد :</em></u><br />&bull; الطفح الجلدي، الحكة .<br /><u><em>الآثار العامة :</em></u><br />&bull; تورم أجزاء من الجسم نتیجة لارتشاح السوائل في الأنسجة (التورم، وخاصة تورم الساقین) .<br /><u><em>الآثار على نتائج الاختبارات البیولوجیة:</em></u><br />&bull; ارتفاع قابل للعكس في مستویات نیتروجین یوریا الدم، زیادة مؤقتة أو قابلة للعكس في مستویات ناقلة أمین مصل الدم (إنزیمات<br />موجودة داخل الخلایا) ،<br />&bull; انخفاض في الھیموجلوبین (بروتین موجود في خلایا الدم الحمراء یحمل الأكسجین إلى الأنسجة ویمنح الدم لونھ الأحمر)<br />والھیماتوكریت (النسبة المئویة للحجم الذي تشغلھ خلایا الدم الحمراء مقارنة بإجمالي حجم الدم) غیر مرتبط بنزیف معدي معوي<br />ملحوظ .<br /><u>إذا حد ثت أي من الأعراض الجانبیة المذكورة أعلاه، یجب علیك إخطار طبیب على الفور والأخذ في الاعتبار إیقاف العلاج .</u><br /><strong>الآثار الضارة غیر الشائعة (قد تصیب ما یصل إلى شخص واحد من بین كل ۱۰۰ شخص) :</strong><br /><u><em>الآثار على العینین:</em></u><br />&bull; تغیم الرؤیة.<br />الآثار القلبیة:<br />&bull; الشعور بضربات القلب (الخفقان) .<br /><u><em>الآثار على الجھاز الھضمي :</em></u><br />&bull; التھاب في الفم<br />الآثار على الاختبارات البیولوجیة:<br />&bull; ارتفاع قابل للعكس في مستویات الكریاتینین في الدم، (قد تكون علامة على مشكلة في الكلى) .<br />إذا حدث أي من الأعراض الجانبیة المذكورة أعلاه، یجب علیك إخطار طبیب على الفور والأخذ في الاعتبار إیقاف العلاج .</p><p dir="RTL"><br /><strong>الآثار الضارة ذات معدل التكرار غیر المعروف (لا یمكن تقدیر معدل التكرار من البیانات المتاحة) :</strong><br /><em><u>الآثار على الدم :</u></em><br />&bull; انخفاض غیر طبیعي في مستویات بعض خلایا الدم، مما قد ینتج عنھ شحوب أو إرھاق شدید (خلایا الدم الحمراء)، أو علامات<br />للإصابة بعدوى أو حمى غیر مبررة (خلایا الدم البیضاء)، أو نزیف من الأنف أو اللثة (الصفیحات الدمویة)، أو ارتفاع غیر طبیعي<br />في مستویات خلایا الدم الأخرى (الیوزینیات) .<br /><u>الآثار على الجھاز المناعي:</u><br />&bull; تفاعلات حساسیة شدیدة (تفاعلات تأقیة) ،<br />&bull; تفاعلات حساسیة شدیدة مرتبطة بظھور الأجسام المضادة (داء المصل).<br /><u>الآثار على الأیض والتغذیة :</u><br />&bull; ارتفاع غیر طبیعي في مستویات جلوكوز الدم (فرط جلوكوز الدم) ،<br />&bull; انخفاض غیر طبیعي في مستویات جلوكوز الدم (نقص جلوكوز الدم) ،<br />&bull; احتباس السوائل، احتباس الصودیوم،</p><p>&bull; ارتفاع مستوى البوتاسیوم في الدم (فرط بوتاسیوم الدم) .<br /><u>الآثار على الجھاز العصبي :</u><br />&bull; تیبس الرقبة المصحوب بالحمى وأحیانًا الغیبوبة (التھاب السحایا العقیم)،<br />&bull; اضطراب الحساسیة الذي یتضمن الشعور باللسع، والخدر، والوخز في أحد الأعضاء الطرفیة، عادةً في الجانب الطرفي (التنمیل) .<br /><u>الآثار على العینین:</u><br />&bull; تھیج العین، تورم العینین.<br /><u>الآثار على الأذن :</u><br />&bull; ضعف السمع .<br /><u>الآثار على الأوعیة الدمویة :</u><br />&bull; التھاب حاد في جدران الأوعیة الدمویة (التھاب الأوعیة الدمویة)،<br />&bull; ضغط الدم المرتفع (الضغط المرتفع).<br /><u>الآثار التنفسیة:</u><br />&bull; انقباض الرئتین الذي یسبب الانسداد المؤقت للمجاري الھوائیة (التشنج القصبي)،<br />&bull; صعوبة التنفس (ضیق التنفس)،<br />&bull; نزیف الأنف (الرعاف) ،<br />&bull; نوبة ربو .<br /><u>الآثار على الجھاز الھضمي :</u><br />&bull; القرح والانثقابات المعدیة المعویة ،<br />&bull; التھاب البنكریاس،<br />&bull; نزیف في الجھاز الھضمي (خروج الدم من الفم (قيء دموي) أو وجود دم في البراز، أو تلوُّن البراز باللون الأسود (التغوط<br />الأسود )). یزداد معدل حدوث ھذا النوع من النزیف مع تلقي جرعات أعلى،<br />&bull; التھاب بطانة المعدة (التھاب المعدة).<br /><u>الآثار الكبدیة الصفراویة :</u><br />&bull; التھاب الكبد الشدید الذي یمكن أن یكون ممیتا،ً<br />&bull; الیرقان (اصفرار الجلد أو العینین).<br /><u>الآثار على الجلد :</u><br />&bull; تبثر، غالبًا ما یكون مصحوبًا بحكة وشعور بالحرقان (شرى) على الوجھ مع صعوبة التنفس (التورم الوعائي) .<br />&bull; تفاعلات جلدیة خطیرة مثل الطفح الجلدي، أو تبثر أو تقشر الجلد (متلازمة ستیفنز- جونسون، تقشّر الأنسجة المتموتة البشرویة<br />تفاعلات جلدیة ،(DRESS) التسممي (متلازمة لایل)، متلازمة التفاعل الدوائي المصحوب بفرط الیوزینیات وأعراض جھازیة<br />فقاعیة، التھاب الجلد التقشري، البقع الحمراء عدیدة الأشكال)،<br />&bull; تفاعل جلدي شدید عند تعرض الجلد لأشعة الشمس أو للأشعة فوق البنفسجیة ،<br />&bull; الطفح الدوائي الثاب ت (قد یظھر بقعاً جلدیة حمراء دائریة أو بیضاویة الشكل وتورم الجلد)، تبثر، غالبًا ما یكون مصحوبًا بالحكة<br />والشعور بالحرقان (الشرى) ،<br />&bull; الفرفریة الوعائیة التي تؤدي إلى ظھور بقع نزفیة على الجلد (ھینوخ- شونلاین)،<br />&bull; انفصال الأظافر التقدمي (انفكاك ا لأظافر)،<br />&bull; تفاقم حالة التبثر، وغالبًا ما ت كون مصحو بة بالحكة والشعور بالحرقان (الشرى المزمن) ،<br />&bull; تساقط الشعر (الثعلبة) .<br /><u>الآثار على الكلى:</u><br />&bull; اضطراب وظیفة ترشیح الكلى (الفشل الكلوي الوظیفي الحاد، المتلازمة الكلویة) ،<br />&bull; التھاب بعض أنسجة الكلى (التھاب كبیبات الكلى، التھاب الكلیة الخلالي)،<br />&bull; نخر في جزء من الكلى (نخر الحلیمات الكلویة، النخر النبیبي الحاد) .<br /><u>الآثار على الجھاز التناسلي :</u><br />&bull; انخفاض الخصوبة في السیدات .<br />الأعراض الجانبیة العامة والمتعلقة بموضع الاستعمال :<br />&bull; تفاعلات ضارة موضعیة (شعور بالحرقان) أو تلف الأنسجة في موضع الحقن،<br />&bull; التوعك،<br />&bull; ألم في موضع الحقن .<br /><u>الآثار على نتائج الاختبارات البیولوجیة:</u><br />&bull; نتیجة إیجابیة لاختبار الأجسام المضادة للنواة،<br />&bull; ارتفاع عابر أو قابل للعكس في مستوى البیلیروبین في الدم،<br />&bull; انخفاض تراكم الصفائح الدمویة وزیادة مدة النزیف .<br />إذا حدثت أي من الأعراض الجانبیة المذكورة أعلاه، یجب علیك إخطار طبیب على الفور والأخذ في الاعتبار إیقاف العلاج .<br /><strong>الإبلاغ عن الأعراض الجانبیة</strong><br />إذا أصبت بأي آثار جانبیة، فتحدث إلى طبیبك أو الصیدلي. یتضمن ھذا أي آثار جانبیة محتملة غیر مدرجة في ھذه النشر ة</p><p>بالإبلاغ عن الآثار الجانبیة، یمكنك المساعدة في توفیر المزید من المعلومات حول سلامة ھذا الدواء .<br /><strong>للإبلاغ عن الأعراض الجانبیة</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&bull; المملكة العربیة السعودیة</strong><br />المركز الوطني للتیقظ الدوائي<br />&bull; مركز الاتصال: ۱۹۹۹۹<br />npc.drug@sfda.gov.sa : &bull; البرید الإلكتروني<br />https://ade.sfda.gov.sa/ : &bull; الموقع الإلكتروني</p></td></tr></tbody></table><p><br /><strong>&bull; دول الخلیج الأخر ى</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>- الرجاء الاتصال بالمؤسسات والھیئات الوطنیة في كل دولة .</em></p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">یحفظ عند درجة حرارة اقل من ۲٥ درجة مئویة.<br />احتفظ بھذا الدواء بعیدًا عن مرأى ومتناول الأطفال .<br />&quot;.EXP&quot; لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المدون على العبوة والقارورة بعد الرمز<br />یشیر تاریخ انتھاء الصلاحیة إلى آخر یوم من الشھر المذكور.<br />ینبغي تخزین ھذا الدواء عند درجة حرارة اقل من ۲٥ درجة مئویة بعیدًا عن الحرارة والرطوبة .<br />لا تتخلص من أي أدویة عبر میاه الصرف أو مع المخلفات المنزلیة. اسأل الصیدلي عن كیفیة التخلص من الأدویة التي لم تعد تستخدمھا.<br />ستساعد ھذه الإجراءات على حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="rtl"><p dir="RTL">&bull; المادة الفعالة هي :<br />بيروكسيكام ......................................................................................................... ۲۰ ملجم للقرص الواحد .<br />&bull; المكونات الأخرى هي:.</p></li></ul><p dir="RTL">لاكتوز أحادي الھیدرات، سلیولوز بلوري مكروي، ھیدروكسي بروبیل سلیولوز، فومارات ستیریل الصودیوم (انظر القسم 2)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">يأتي هذا الدواء في صورة أقراص سريعة الذوبان. عبوة بها ۱۰ أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u><strong>مالك رخصة التسوی ق</strong></u><br />سبیماكو، القصیم، المملكة العربیة السعودیة<br /><u><strong>الجھة المصنعة</strong></u><br />سبیماكو، القصیم، المملكة العربیة السعودیة<br />بترخیص من شركة فایزر الأمریكیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على ھذه النشرة بتاریخ يناير /كانون الثاني ۲۰۲۳
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FELDENE  20 mg, dispersible tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Piroxicam…………………………………………………………………………20.0 mg
For one tablet.
Excipients with known effect: lactose, sodium.
This medicine contains less than 1 mmol sodium (23 mg) per tablet. 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dispersible tablet. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Piroxicam is indicated for the symptomatic treatment of arthritis, rheumatoid polyarthritis or ankylosing spondylitis. Because of its tolerance profile (see sections 4.2, 4.3 and 4.4), piroxicam must not be used as a first-line treatment when treatment with NSAIDs is indicated.</p><p>The decision to prescribe a product containing piroxicam should be based on evaluation of the totality of each patient&rsquo;s specific risks (see sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp;<u>Posology</u></p><p>Prescription of products containing piroxicam should be initiated by doctors experienced in the diagnosis and treatment of patients with inflammatory or degenerative rheumatic diseases.</p><p>The maximum recommended daily dose is 20 mg.</p><p>The onset of side effects can be minimised by using the lowest possible dose necessary to relieve symptoms during the shortest possible treatment period. The benefits and safety of using the treatment should be re-evaluated within 14 days. If it is necessary to continue the treatment, it should be re- evaluated frequently.</p><p>If the use of piroxicam is associated with increased risk of gastrointestinal complications, treatment to protect the gastric mucosa (e.g. misoprostol or proton pump inhibitors) should be seriously considered, especially in elderly patients.</p><p>&nbsp;</p><p><u>Frequency of administration</u></p><p>The tablet should be taken during a meal.</p><p>&nbsp;</p><p><u>Slow CYP2C9 metabolisers</u></p><p>Given the risk of dose-dependent side effects, it is advisable to administer piroxicam with caution to patients who are known to be or suspected of being slow CYP2C9 metabolisers, based on case histories/previous experience with other CYP2C9 substrates. A dose reduction should be considered (see section 5.2).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Oral use.</p><p>The tablet should be swallowed as is or dissolved in a large glass of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This medicinal product is contraindicated in the following situations:
•	hypersensitivity to the active substance or to any of the excipients listed in section 6.1,
•	pregnancy, from the start of the 6th month (beyond 24 weeks of amenorrhoea) (see section 4.6),
•	history of allergy or asthma triggered by taking piroxicam or substances with similar activity such as other NSAIDs, aspirin,
•	history of serious allergic reactions to medicines of any type, in particular cutaneous reactions such as polymorphous erythema, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome),
•	history of ulcers, haemorrhage or gastrointestinal perforation,
•	patients with a history of gastrointestinal disorders predisposing them to haemorrhagic disorders such as haemorrhagic rectocolitis, Crohn’s disease, gastrointestinal cancers or diverticulitis,
•	patients with ongoing peptic ulcer, an inflammatory gastrointestinal disorder or gastrointestinal haemorrhage,
•	severe hepatocellular impairment,
•	severe heart failure,
•	severe renal impairment,
•	children under 15 years of age,
•	aortocoronary bypass surgery,
•	in combination with mifamurtide (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Special warnings</u></strong></p><p>The concomitant use of piroxixam with other NSAIDs, including cyclooxygenase 2 (cox-2) selective</p><p>inhibitors, should be avoided.</p><p>The onset of side effects can be minimised by using the weakest possible dose for the shortest possible treatment period needed for relief of symptoms (see section 4.2 and the paragraphs on &ldquo;Gastrointestinal manifestations &rdquo;and &ldquo;Cardiovascular and cerebrovascular effects &rdquo;below).</p><p>The clinical benefit and the safety of use should be re-evaluated periodically. Treatment should be stopped immediately at the first sign of cutaneous reaction or symptomatic gastrointestinal events.</p><p>Patients with asthma associated with chronic rhinitis, chronic sinusitis and/or nasal polyposis have a higher risk than the general population of allergic events when they take aspirin and/or non-steroidal anti-inflammatories.</p><p>Administration of this medicine can trigger an asthmatic crisis, especially in certain subjects who are allergic to aspirin or an NSAID (see section 4.3).</p><p><em><u>Gastrointestinal (GI) manifestations: risk of ulcers, haemorrhages and GI perforation</u></em></p><p>NSAIDs, including piroxicam, may trigger serious gastrointestinal side effects, especially haemorrhage, gastric ulcers and perforations, in the small intestine or large intestine, some of which can be fatal. Administration of doses greater than 20 mg per day increases the risk of gastrointestinal side effects. Studies have suggested that piroxicam may be associated with a higher risk of severe gastrointestinal toxicity than other NSAIDs. These serious side effects can arise at any time, not necessarily with warning signs, in any patient treated with NSAIDs.</p><p>Regardless of the duration, any treatment with NSAIDs increases the risk of serious GI side effects. Patients presenting risk factors for serious GI side effects should only be treated with piroxicam after a detailed evaluation of the risk/benefit ratio (see section 4.3 and below).</p><p>The possibility of using a treatment that protects the gastric mucosa (e.g. misoprostol or proton pump inhibitors) should be seriously considered (see section 4.2).</p><p><em><u>Serious GI complications</u> <u>Identification of patients at risk</u></em></p><p>The incidence of serious GI complications increases with age. An increased risk of complications exists for patients over 70 years of age. Administration to patients aged over 80 years of age should be avoided. Patients receiving concomitant treatments such as oral corticoids, selective serotonin reuptake inhibitors (SSRI) or platelet antiaggregants such as low doses of acetylsalicylic acid have an increased risk of serious GI complications (see below and section 4.5), in the same way as with patients consuming</p><p>&nbsp;</p><p>alcohol. As with other NSAIDs, the use of piroxicam in association with gastric mucosal protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for patients at risk.</p><p>Both patients and doctors must be vigilant in detecting possible signs and symptoms of ulcers and/or gastric haemorrhage in the course of piroxicam treatment. Patients should be asked to report any new or unusual abdominal symptoms during treatment. If a gastrointestinal complication is suspected during treatment, piroxicam should be discontinued immediately. A complementary clinical evaluation and alternative treatments should be considered.</p><p><em><u>Cardiovascular (CV) and cerebrovascular effects</u></em></p><p>Appropriate monitoring and specific recommendations are applicable to patients with a history of hypertension and/or mild to moderate heart failure, as cases of water/salt retention and oedema have been reported in association with NSAIDs.</p><p>Clinical studies and epidemiological data suggest that the use of certain NSAIDs (especially at high doses and long term) can be associated with a slight increase in the risk of potentially fatal arterial thrombotic events (for example, myocardial infarction or cerebrovascular accident). The increase in relative risk appears to be similar in all patients, whether or not they present with CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors for CV disease may have a higher risk in terms of absolute impact, due to the higher initial risk. Currently available data are insufficient to rule out this increase in risk with piroxicam.</p><p>Patients with uncontrolled hypertension, congestive heart failure, ischaemic cardiopathy, peripheral arterial disease, and/or a history of cerebrovascular accidents (including transitory ischaemic accidents) should only be treated with piroxicam after a careful evaluation of the risk/benefit ratio.</p><p>Patients with CV disease may be at an increased risk of aggravation of heart failure. Doctors and patients should be warned of this risk, even in the absence of previous CV symptoms. Patients must also be informed of the signs and symptoms of severe cardiac toxicity and the actions to be taken if they occur (see section 4.3).</p><p>The same attention is required before initiating any long-term treatment in patients presenting risk factors for cardiovascular pathology (such as hypertension, hyperlipidaemia, diabetes or tobacco use).</p><p><em><u>Hypertension</u></em></p><p>As with all NSAIDs, piroxicam may cause the onset of high blood pressure, or an increase of existing hypertension, which can contribute to an increased incidence of cardiovascular effects. NSAIDs, including piroxicam, should be used with caution in hypertensive patients. Blood pressure should be monitored closely the start of treatment and throughout its duration.</p><p><em><u>Hepatic reactions</u></em></p><p>Severe liver disease (jaundice, severe or fatal hepatitis) have rarely been reported with piroxicam. If abnormalities in hepatic function persist or become worse, or if clinical signs of hepatic impairment or general signs (eosinophilia, rash) arise, treatment with piroxicam must be discontinued.</p><p><em><u>Skin reactions</u></em></p><p>Serious skin reactions, some of which have fatal outcomes, including drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell syndrome), have been reported in very rare cases in association with NSAID treatment (see section 4.8). Cases of fixed drug eruption (FDE) have been reported with piroxicam. Piroxicam should not be reintroduced in patients with history of piroxicam-related FDE. Potential cross reactivity might occur with other oxicams.</p><p>Studies have suggested that piroxicam could be associated with an increased risk of serious cutaneous reactions compared to other NSAIDs that are not oxicam derivatives. The incidence of these side effects seems to be more significant at the start of treatment, in the majority of cases during the first month of treatment. Treatment with piroxicam should be stopped upon appearance of a cutaneous rash, mucosal lesions or any other sign of hypersensitivity.</p><p><em><u>Functional renal impairment</u></em></p><p>By inhibiting the vasodilator action of renal prostaglandins, NSAIDs can trigger functional renal impairment by decreasing glomerular filtration.</p><p>At the start of treatment, monitoring of diuresis and renal function is recommended for patients presenting the following risk factors:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; elderly patients,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines administered concomitantly, such as: ACE inhibitors, ARBs, diuretics (see section 4.5),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypovolaemia, regardless of the cause,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic renal impairment,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nephrotic syndrome,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lupus nephritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decompensated hepatic cirrhosis.</p><p>Particular attention must be paid upon starting treatment with piroxicam in patients with severe dehydration. Monitoring is also recommended in patients with renal impairment (see section 4.3) Because of the substantial elimination of piroxicam and its biotransformation products by the kidneys, lower doses of piroxicam should be considered in patients with impaired renal function, and these patients should be closely monitored (see sections 4.3 and 5.2).</p><p><em><u>Use with oral anticoagulants</u></em></p><p>The concomitant use of NSAIDs, including piroxicam, with oral anticoagulants increases the risk of gastrointestinal and non-gastrointestinal bleeding and should be avoided. Oral anticoagulants include warfarin anticoagulants/coumarin and direct oral anticoagulants (for example apixaban, dabigatran, rivaroxaban). Anticoagulation/the INR should be monitored in patients taking warfarin/coumarin-type anticoagulants (see section 4.5).</p><p><em><u>Fluid retention</u></em></p><p>Water/salt retention with possible oedema, hypertension or increased hypertension, exacerbation of heart failure. Clinical monitoring is necessary at the beginning of treatment in case of hypertension or heart failure. A decrease in the effect of antihypertensive medicines is possible (see section 4.5).</p><p><em><u>Hyperkalaemia</u></em></p><p>Hyperkalaemia caused by diabetes or treatment with hyperkalaemiant medicines (see section 4.5). Regular monitoring of blood potassium level is necessary under these circumstances.</p><p><em><u>Elderly patients</u></em></p><p>Elderly patients have an increased risk of side effects to NSAIDs, in particular gastrointestinal haemorrhage and perforations, which can be fatal (see section 4.2).</p><p>In prescribing, the doctor should take into account the fact that cases of secondary anovulatory infertility caused by non-rupture of the De Graaf follicle, reversible when treatment is stopped, have been described in patients receiving long-term treatment with certain prostaglandin synthesis inhibitors.</p><p><em><u>Excipients</u></em></p><p>This medicinal product contains lactose. Patients with galactose intolerance, total lactase deficiency, or malabsorption of glucose and galactose syndrome (rare hereditary diseases) should not take this medicine.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &quot;sodium-free&quot;.</p><p>&nbsp;</p><p><strong><u>Precautions for use</u></strong></p><p>This medicine is available in other dose forms that may be more appropriate.</p><p>The onset of an asthma crisis in certain patients may be linked to an allergy to aspirin or to NSAIDS (see section 4.3).</p><p>Suitable monitoring is necessary for patients with a history of hypertension and/ heart failure, as cases of water/salt retention and oedema have been reported in connection with NSAID treatment.</p><p><strong>Poor metabolisers of CYP2C9 substrates</strong></p><p>Piroxicam should be administered to patients known or suspected to be poor metabolisers of CYP 2C9 with caution, based on previous experience with other CYP2C9 substrates, as abnormally high plasma concentrations of piroxicam may occur due to its decreased metabolism (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Simultaneous administration of piroxicam with the following products requires rigorous monitoring of the patient&rsquo;s clinical and biological state.</p><p>&nbsp;</p><p><strong><u>Contraindicated combinations</u></strong></p><p>+&nbsp;&nbsp;&nbsp; <strong>Mifamurtide</strong></p><p>At high doses of NSAIDs, risk of less effective mifamurtide.</p><p><strong><u>Inadvisable combinations</u></strong></p><p>+&nbsp;&nbsp;&nbsp; <strong>Acetylsalicylic acid at anti-inflammatory doses (&ge;1 g per dose and/or &ge;3 g per day) or at</strong></p><p><strong>analgesic or antipyretic doses (&ge;500 mg per dose and/or &lt;3 g per day)</strong></p><p>Increased risk of digestive ulcers and haemorrhage.</p><p><strong>+&nbsp;&nbsp;&nbsp; Oral anticoagulants</strong></p><p>NSAIDs, including piroxicam, are likely to enhance the effects of anticoagulants, such as coumarin-type derivatives (warfarin) and direct oral anticoagulants (for example, apixaban, dabigatran, rivaroxaban). Increase in the risk of haemorrhage from oral anticoagulant (aggression of the gastroduodenal mucosa by non-steroidal anti-inflammatories). Consequently, the concomitant use of piroxicam and anticoagulants should be avoided. If the association cannot be avoided, carry out close clinical, or even biological, monitoring (see section 4.4).</p><p><strong>+&nbsp;&nbsp;&nbsp; Other non-steroidal anti-inflammatories (including aspirin and other salicylates)</strong></p><p>With other non-steroidal anti-inflammatories: increased risk of digestive ulcers and bleeding.</p><p>As with all NSAIDs, the use of piroxicam combined with acetylsalicylic acid or other NSAIDs, and the combination of several proprietary medicinal products containing piroxicam, must be avoided. No data has made it possible to demonstrate the benefit of these combinations compared with piroxicam alone, and therefore the incidence of adverse effects is increased (see section 4.4).</p><p>Human studies have highlighted a reduced piroxicam plasma concentration of approximately 80% of the usual value during the concomitant administration of piroxicam and acetylsalicylic acid.</p><p><strong>+&nbsp;&nbsp;&nbsp; Heparins of low molecular weight and related substances (curative doses and/or elderly patients)</strong></p><p>Increased risk of bleeding for oral anticoagulants (aggression of the gastroduodenal mucosa by non- steroidal anti-inflammatories). If the combination cannot be avoided, ensure close clinical monitoring.</p><p><strong>+&nbsp;&nbsp;&nbsp; Unfractionated heparins (curative doses and/or elderly patients)</strong></p><p>Increased risk of bleeding for oral anticoagulants (aggression of the gastroduodenal mucosa by non- steroidal anti-inflammatories). If the combination cannot be avoided, ensure close clinical monitoring.</p><p>+&nbsp;&nbsp;&nbsp; <strong>Lithium</strong></p><p>Increase of lithaemia that can reach toxic levels (decrease in the renal excretion of lithium).</p><p>If the combination cannot be avoided, closely monitor lithium levels and adapt the lithium dose both during concomitant treatment and after stopping the non-steroidal anti-inflammatories.</p><p><strong>+&nbsp;&nbsp;&nbsp; Methotrexate administered at doses greater than 20 mg/week</strong></p><p>Increase in haematological toxicity for methotrexate (decreased renal elimination of methotrexate with anti-inflammatories).</p><p><strong>+&nbsp;&nbsp;&nbsp; Nicorandil</strong></p><p>Increased risk of digestive ulcers and bleeding.</p><p><strong>+&nbsp;&nbsp;&nbsp; Pemetrexed (in patients with mild to moderate renal function):</strong></p><p>Risk of increasing the toxicity of pemetrexed (decrease in renal clearance caused by NSAIDs).</p><p><strong><u>Combinations requiring precautions for use</u></strong></p><p>+&nbsp;&nbsp;&nbsp; <strong>Angiotensin II receptor antagonists</strong></p><p>Acute renal impairment in at-risk patients (elderly, dehydration, concomitant treatment with diuretics, renal function impairment), due to decreased glomerular filtration secondary to a decrease in synthesis of renal prostaglandins. These effects are usually reversible. In addition, reduction of the anti- hypertensive effect.</p><p>Hydrate the patient and monitor renal function at baseline and periodically throughout the combination.</p><p><strong>+&nbsp;&nbsp;&nbsp; Ciclosporin</strong></p><p>Risk of additional nephrotoxic effects, particularly in elderly subjects. Monitor renal function at the beginning of treatment with NSAIDs.</p><p>+ Cobimetinib</p><p>Increased haemorrhagic risk. Clinical monitoring.</p><p><strong>+&nbsp;&nbsp;&nbsp; Diuretics</strong></p><p>Acute renal failure in at-risk the patient (elderly, dehydrated, on diuretics, with impaired renal function) by decreasing glomerular filtration secondary to a decrease in synthesis of renal prostaglandins. These effects are usually reversible. In addition, reduction of the anti-hypertensive effect.</p><p>Hydrate the patient and monitor renal function at the start of treatment and regularly during the combination.</p><p><strong>+&nbsp;&nbsp;&nbsp; Angiotensin-converting enzyme inhibitors</strong></p><p>Acute renal failure in at-risk patient (elderly, dehydrated, diuretic-treated, impaired renal function), due to decreased glomerular filtration secondary to a decrease in synthesis of renal prostaglandins. These effects are generally reversible. In addition, reduction of the anti-hypertensive effect.</p><p>Hydrate the patient and monitor renal function at baseline and periodically throughout the combination.</p><p><strong>+&nbsp;&nbsp;&nbsp; Methotrexate, used at low doses (lower than or equal to 20 mg/week)</strong></p><p>Increase in haematological toxicity for methotrexate (decreased renal elimination of methotrexate with anti-inflammatories).</p><p>Weekly monitoring of the CBC during the first weeks of the combination. Increased monitoring in case of changes (even slight) in renal function as well as for elderly patients.</p><p><strong>+&nbsp;&nbsp;&nbsp; Pemetrexed in patients with normal renal function</strong></p><p>Risk of increasing the toxicity of pemetrexed (decrease in renal clearance caused by NSAIDs). Biological monitoring of renal function.</p><p><strong>+&nbsp;&nbsp;&nbsp; Tacrolimus</strong></p><p>Risk of additional nephrotoxic effects, particularly in elderly patients. Renal function should be monitored at the start of treatment with NSAIDs.</p><p><strong>+&nbsp;&nbsp;&nbsp; Tenofovir disoproxil</strong></p><p>Risk of increased nephrotoxicity due to tenofovir, particularly with high doses of the anti-inflammatory or in the presence of risk factors for renal impairment.</p><p>When used in combination, renal function should be monitored.</p><p>&nbsp;</p><p><strong><u>Combinations to be taken into account</u></strong></p><p>+&nbsp;&nbsp;&nbsp; <strong>Acetylsalicylic acid at anti-aggregating doses (from 50 mg to 375 mg per day in one or more doses)</strong></p><p>Increased risk of gastrointestinal ulcers and haemorrhage.</p><p>Piroxicam, like other NSAIDs, decreases platelet aggregation and prolongs bleeding time. This effect must be taken into account when determining the bleeding time.</p><p>Piroxicam interferes with the anti-platelet effect of aspirin at low doses, and may therefore interfere with the prophylactic effect of aspirin in the treatment of CV disease.</p><p><strong>+&nbsp;&nbsp;&nbsp; Platelet anti-aggregants</strong></p><p>Increased risk of bleeding, especially gastrointestinal.</p><p><strong>+&nbsp;&nbsp;&nbsp; Other potassium-sparing agents</strong></p><p>Risk of potentially fatal increase in hyperkalaemia.</p><p>&nbsp;</p><p><strong><u>Risk related to hyperkalaemia</u></strong></p><p>Certain medicines or therapeutic classes may predispose patients to the occurrence of hyperkalaemia: potassium salts, potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin II antagonists, non-steroidal anti-inflammatory agents, heparin (low molecular weight or unfractionated), immunosuppressants such as ciclosporin or tacrolimus, trimethoprim.</p><p>The combination of these medicines increases the risk of hyperkalaemia. This risk is particularly significant with potassium-sparing diuretics, especially when combined with each other or with potassium salts, whereas the combination of an ACE inhibitor and an NSAID, for example, is safer provided the recommended precautions are taken.</p><p>To learn more about the risks and restriction levels of specific potassium-sparing agents, physicians should refer to the interactions specific to each substance.</p><p>However, some substances, such as trimethoprim, are not subject to specific interactions in relation to this risk. Nevertheless, they may act as predisposing factors when combined with other medicines already mentioned in this section.</p><p>Onset of hyperkalaemia can depend on the presence of co-associated factors.</p><p><strong>+&nbsp;&nbsp;&nbsp; Beta blockers (except esmolol) (including eye drops)</strong></p><p>Reduction in the antihypertensive effect (inhibition of vasodilator prostaglandins by non-steroidal anti- inflammatories).</p><p><strong>+&nbsp;&nbsp;&nbsp; Deferasirox</strong></p><p>Increased risk of digestive ulcers and haemorrhage.</p><p><strong>+&nbsp;&nbsp;&nbsp; Glucocorticoids (except hydrocortisone)</strong></p><p>Increased risk of gastrointestinal ulcers and haemorrhage (see section 4.4).</p><p><strong>+&nbsp;&nbsp;&nbsp; Unfractionated heparins and low-molecular weight heparins and related (prophylactic doses)</strong></p><p>Increased risk of haemorrhage.</p><p><strong>+&nbsp;&nbsp;&nbsp; Selective serotonin reuptake inhibitors (SSRI)</strong></p><p>Increased risk of haemorrhage (see section 4.4).</p><p><strong>+ Mixed adrenergic-serotonergic drugs</strong></p><p>Increased haemorrhagic risk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>Inhibition of prostaglandin synthesis by NSAIDs may affect the course of pregnancy and/or the development of the embryo or foetus.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="rtl"><img width="273" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><u>Risks related to the use during the 1<sup>st</sup> trimester</u></p><p>Data of epidemiological studies suggests an increase in the risk of miscarriage, heart malformations and gastroschisis, after treatment by a prostaglandin synthesis inhibitor at the start of pregnancy. The absolute risk of cardiovascular malformations went from less than 1% in general population to approximately 1.5% in people exposed to NSAIDs. The risk appears to increase with dose and treatment duration. In animals, it has been shown that the administration of a prostaglandin synthesis inhibitor causes an increased risk of pre- and post-implant loss and a rise in embryo-foetal fatality. Moreover, a higher incidence of certain malformations, including cardiovascular malformations, has been reported in animals who received a prostaglandin synthesis inhibitor during the organogenesis phase of gestation.</p><p dir="rtl">&nbsp; &nbsp;</p><p dir="rtl"><u>&nbsp;Risks related to the use from the 12<sup>th</sup>week of amenorrhoea and until birth<sup>&nbsp;</sup>&nbsp;</u></p><p>From the 12<sup>th</sup> week of amenorrhoea and until birth, all NSAIDs, by inhibition of prostaglandin synthesis, may expose the foetus to <strong>renal function disorder:</strong></p><p>o&nbsp;&nbsp; <em>in utero </em>observed from 12 weeks of amenorrhoea (start of foetal diuresis): oligoamnios (may occur shortly after starting treatment and is generally reversible after discontinuation of treatment), or anamnios, especially after extended exposure.</p><p>o&nbsp;&nbsp; at birth, renal impairment (reversible or irreversible) can persist, particularly in case of late and prolonged exposure (with a risk of severe delayed hyperkalaemia).</p><p>The constriction of the arterial canal may occur during the second trimester (usually reversible upon discontinuation of the treatment).</p><p dir="rtl"><!--[if gte vml 1]><v:shape id="Graphic_x0020_10"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:70.9pt;margin-top:11.5pt;width:327.75pt;height:.5pt;z-index:15730688;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 v-text-anchor:top' coordsize="4162425,6350" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m4162044,l,,,6096r4162044,l4162044,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="437" height="1" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />R<u>isks related to the use from the 24<sup>th</sup> week of amenorrhoea and until birth</u>:</p><p>From the 24<sup>th</sup> week of amenorrhea, NSAIDs may expose the foetus to <strong>cardiopulmonary toxicity </strong>(premature closure of the ductus arteriosus and pulmonary arterial hypertension) and lead to foetal or neonatal right heart failure or foetal death <em>in utero</em>. This risk is greater the closer administration is to delivery (less reversibility). This effect occurs even with occasional administration.</p><p><u>At the end of pregnancy, the mother and newborn may have:</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased bleeding time due to an anti-aggregating action, which may arise even after the administration of very small doses of the medicinal product;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an inhibition of uterine contractions, resulting in a delay in term or prolonged delivery.</p><p><u>Consequently:</u></p><p>Unless absolutely necessary, this medicinal product must not be prescribed in a woman considering pregnancy or during the first 5 months of pregnancy (first 24 weeks of amenorrhoea). If this medicinal product is administered to a woman intending to get pregnant or who is less than 6 months pregnant, the dose should be as low as possible and the duration of treatment as short as possible. Prolonged use is highly inadvisable. The health care professionals should consider ultrasound monitoring of amniotic fluid if NSAID treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found.</p><p>Administration from the 20<sup>th</sup> week of amenorrhoea justifies cardiac and renal monitoring. In the event of oligoamnios, or constriction of the arterial canal, treatment with this medicine should be discontinued. From the beginning of the 6<sup>th</sup> month (after 24 weeks of amenorrhoea): any ongoing administration, however brief, is contraindicated. An inadvertent use from this date requires cardiac and renal monitoring of the foetus or neonate, depending on the date of exposure. The duration of this monitoring depends on the elimination half-life of the molecule.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Because NSAIDs pass into breast milk, this medicinal product is not recommended for use by breast- feeding women.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Like all NSAIDs, the use of this medicinal product may temporary affect female fertility by acting on ovulation. It is therefore not recommended for women wishing to conceive a child. In women having difficulty conceiving or undergoing fertility tests, discontinuation of treatment should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Warn patients of possible vertigo or drowsiness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical studies and epidemiological data suggest that the use of certain NSAIDs (especially at high doses and long term) can be associated with a slight increase in the risk of arterial thrombotic events (for example, myocardial infarction or cerebrovascular accident) (see section 4.4).</p><p>The most frequently observed side effects are gastrointestinal in nature. Peptic ulcers, gastrointestinal perforations or haemorrhages, sometimes fatal, can occur, especially in elderly patients (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, ulcerative stomatitis, abdominal pain, melaena, haematemesis, aggravation of rectocolitis or Crohn&rsquo;s disease (see section 4.4) have been reported after administration of NSAIDs. Less frequently, gastritis has been observed.</p><p>Oedema, hypertension and heart failure have been reported in association with NSAID treatment.</p><p>The table below presents adverse drug reactions (ADRs) by system organ class (SOC) and frequency category. The ADRs are listed in order of decreasing medical seriousness within each frequency category and SOC.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge; 1/100 to &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge; 1/1000 to &lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known (cannot be estimated from the</strong></p><p><strong>available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aplastic anaemia* (Aplasia bone marrow)<sup>a</sup></p><p>Haemolytic anaemia* Eosinophilia* Leucopenia*</p><p>Thromocytopenia*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylaxis* Serum sickness*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperglycaemia* Hypoglycaemia* Fluid retention* Sodium retention*</p><p>Hyperkalaemia*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache Dizziness Somnolence</p><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aseptic meningitis* Paresthesia*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blurred vision</p></td><td style="vertical-align:top"><p>Eye irritation* Swollen eyes*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hearing decreased*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasculitis* Hypertension*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchospasm* Dyspnoea* Epistaxis*</p><p>Asthma crisis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Epigastric heaviness Nausea Constipation</p><p>Abdominal discomfort Flatulence</p><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Stomatitis</p></td><td style="vertical-align:top"><p>Perforation* Ulcers* Pancreatitis* Gastrointestinal bleeding (including</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge; 1/100 to &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge; 1/1000 to &lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known (cannot be estimated from the</strong></p><p><strong>available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea Vomiting</p><p>Indigestion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hematemesis and melena)*</p><p>Gastritis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatal hepatitis*</p><p>Severe hepatitis* Jaundice*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Skin rash Pruritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Edema Quincke&#39;s* (Angioedema*) Stevens-Johnson syndrome*</p><p>Toxic epidermal necrolysis (Lyell&#39;s disease)*</p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)* Vesiculo bullous reactions*</p><p>Dermatitis exfoliative* Erythema multiforme* Photosensitisation* Fixed Drug Eruption* Non- thrombocytopenic purpura (Henoch- Schoenlein)* Onycholysis* Worsening of chronic urticaria*</p><p>Alopecia*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Functional acute renal failure*</p><p>Nephrotic syndrome* Glomerulonephritis* Interstitial nephritis* Papillary necrosis* Acute tubular</p><p>necrosis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Female fertility decreased*</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Oedema (mainly of lower extremities)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Malaise*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Reversible elevations of BUN</p><p>Transitory or reversible increased serum transaminase levels</p><p>Decreases in hemoglobin and hematocrit</p><p>unassociated with</p></td><td style="vertical-align:top"><p>Reversible elevations of creatinine</p></td><td style="vertical-align:top"><p>Positive ANA* Transitory or reversible increased bilirubin*</p><p>Platelet aggregation decreased and Bleeding time increased*</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge; 1/100 to &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge; 1/1000 to &lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known (cannot be estimated from the</strong></p><p><strong>available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>obvious gastro- intestinal bleeding</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a. Aplastic anemia is a form of bone marrow failure (aplasia bone marrow).</p><p>*ADR identified post-marketing.</p><p>ANA = antinuclear antibody; BUN = blood urea nitrogen.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Reporting of suspected side effects</u></strong></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_11" o:spid="_x0000_s1027" type="#_x0000_t202"
  style='position:absolute;margin-left:88.9pt;margin-top:12.85pt;width:261pt;
  height:55pt;z-index:-15726080;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".16967mm">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-left:5.15pt;line-height:12.6pt;
     mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'>National<span
     style='letter-spacing:-.4pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.4pt'> </span>Center<span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.2pt'>(NPC)</span><o:p></o:p></b></p>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:12.6pt;
     mso-line-height-rule:exactly'>SFDA<span style='letter-spacing:-.35pt'> </span>Call<span
     style='letter-spacing:-.1pt'> </span>center:<span style='letter-spacing:
     -.1pt'> </span><span style='letter-spacing:-.2pt'>19999</span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:83.1pt;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt'>E-mail: <a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext'>npc.drug@sfda.gov.sa</span></a>
     Website:<span style='letter-spacing:-.7pt'> </span><u>https://ade.sfda.gov.sa/</u><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>SFDA Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: <u>https://ade.sfda.gov.sa/</u></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_12" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:87.5pt;margin-top:18.2pt;width:260.8pt;height:13.2pt;z-index:-15725568;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".48pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:13.4pt;margin-bottom:.0001pt'>-<span style='letter-spacing:
     2.95pt'> </span><i style='mso-bidi-font-style:normal'>Please<span
     style='letter-spacing:-.1pt'> </span>contact<span style='letter-spacing:
     -.2pt'> </span>the<span style='letter-spacing:-.15pt'> </span>relevant<span
     style='letter-spacing:-.2pt'> </span>competent<span style='letter-spacing:
     -.2pt'> </span><span style='letter-spacing:-.1pt'>authority.</span><o:p></o:p></i></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_11" o:spid="_x0000_s1027" type="#_x0000_t202"
  style='position:absolute;margin-left:88.9pt;margin-top:12.85pt;width:261pt;
  height:55pt;z-index:-15726080;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".16967mm">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-left:5.15pt;line-height:12.6pt;
     mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'>National<span
     style='letter-spacing:-.4pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.4pt'> </span>Center<span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.2pt'>(NPC)</span><o:p></o:p></b></p>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:12.6pt;
     mso-line-height-rule:exactly'>SFDA<span style='letter-spacing:-.35pt'> </span>Call<span
     style='letter-spacing:-.1pt'> </span>center:<span style='letter-spacing:
     -.1pt'> </span><span style='letter-spacing:-.2pt'>19999</span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:83.1pt;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt'>E-mail: <a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext'>npc.drug@sfda.gov.sa</span></a>
     Website:<span style='letter-spacing:-.7pt'> </span><u>https://ade.sfda.gov.sa/</u><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>- <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediate transfer to a hospital.</p><p>In the event of acute overdosage with piroxicam, supportive and symptomatic therapy is indicated. There are no specific antidotes. Emesis and/or gastric lavage and/or activated charcoal may be considered dependent upon amount ingested and time since ingestion. Studies indicate that administration of activated charcoal may result in reduced absorption and re-absorption of piroxicam thus reducing the total amount of active drug available.</p><p>Although there are no studies to date, hemodialysis is probably not useful in enhancing elimination of piroxicam since the drug is highly protein-bound.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic&nbsp; group:&nbsp; NON-STEROIDAL&nbsp; ANTI-INFLAMMATORY,&nbsp; ATC&nbsp; code:</strong></p><p><strong>M01AC01.</strong></p><p>Piroxicam is a non-steroidal anti-inflammatory in the oxicam group. It has the following properties:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; analgesic action,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antipyretic action,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-inflammatory activity,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhibitory action on platelet function.</p><p>All these properties are linked to inhibition of prostaglandin synthesis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of piroxicam are linear. Various studies have shown that the pharmacokinetics of piroxicam are not modified with the patient&rsquo;s age. The gel capsules and tablets are bioequivalent.</p><p><u>Absorption</u></p><p>Administered orally, piroxicam is rapidly absorbed (absorption half-life: 50 minutes).</p><p>The overall bioavailability and the degree of absorption are not modified by food, although food delays the absorption rate slightly.</p><p><u>Distribution</u></p><p>The elimination half-life: approximately 50 hours.</p><p>After oral administration of a 20 mg piroxicam gel capsule, the Cmax is 1.85 &mu;g/mL in 1 hour (Tmax) and</p><p>3.72 &mu;g/mL in 1 hour (Tmax) after administration of 40 mg. Binding to plasma proteins is significant: approximately 99%.</p><p>Piroxicam passes over the synovial membrane rapidly: synovial concentrations are, on average, 45 to 50% of blood concentrations.</p><p>Binding to synovial fluid proteins is the same as the binding to plasma proteins.</p><p>A preliminary study has shown that piroxicam is present in breast milk (approximately 1 to 3% of plasma concentration).</p><p><u>Biotransformation - Elimination</u></p><p>Piroxicam is eliminated slowly. It is almost completely metabolised.</p><p>Less than 5% of the ingested dose is eliminated unchanged in the urine and faeces.</p><p>Piroxicam is primarily metabolised by cytochrome P450 CYP 2C9 in the liver. One of the important metabolic pathways is hydroxylation of the pyridyl group in the side chain of piroxicam, followed by glycuro conjugation and elimination in the urine.</p><p>The serum concentration measured after one year of continuous oral administration of 20 mg/day of piroxicam are equivalent to those of the equilibrium originally attained.</p><p>One study evaluated the pharmacokinetics of piroxicam administered as single dose of 20 mg to healthy volunteers presenting a CYP2C9*1/*1, CYP2C9*1/*2, or CYP2C9*1/*3 genotype. During the study, an increase in and a reduction in oral clearance of prioxicam was seen in subjects with CYP2C9*1/*2 or CYP2C9*1/*3 genotype. An increase in inhibition of Cyclooxygenase I by piroxicam was also observed for these patients.</p><p>It is advisable to administer piroxicam with caution to patients who are known to be or suspected of being slow CYP2C9 metabolisers, as an abnormally high plasma piroxicam concentration may occur due to decreased metabolism (see section 4.4).</p><p><u>Pharmacogenetics</u></p><p>The activity of CYP2C9 is decreased in individuals with certain genetic polymorphisms, for example the polymorphisms CYP2C9*2 and CYP2C9*3. Limited data from two published reports have shown that subjects with heterozygous genotypes CYP2C9*1/*2 (n = 9), heterozygous CYP2C9*1/*3 (n = 9) and homozygous CYP2C9*3/*3 (n = 1) had systemic levels of piroxicam respectively 1.7, 1.7 and 5.3 times higher than subjects with the CYP2C9*1/*1 genotype (n = 17, normal metabolisers) following administration of a single oral dose. Mean values for the elimination half-life of piroxicam in patients with genotypes CYP2C9*1/*3 (n = 9) and CYP2C9*3/*3 (n = 1) were respectively 1.7 and 8.8 times higher than those of subjects with the CYP2C9 *1/*1 genotype (n = 17). It is estimated that the frequency of the homozygous *3/*3 genotype is 0 % to 5.7 % across different ethnic groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, microcrystalline cellulose (AVICEL), hydroxypropyl cellulose, sodium stearyl&nbsp;fumarate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life: 24 months.

Do not use Feldene after the expiry date which is stated on the carton after EXP:. The expiry date refers to the last day of that month.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25 &deg;C away from heat and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 tablets in blister.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children. No special requirements.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO, Al-Qassim Pharmacaeutical Plant, Saudi Arabia

MANUFACTURED BY:
SPIMACO, Al-Qassim Pharmacaeutical Plant, Saudi Arabia Under license from: Pfizer Inc, New York, U.S.A.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>